Carcinoma of the bladder in renal transplant patients. A case report and collective review of cases.
Bladder malignancy in the renal transplant recipient is an infrequent occurrence. The 11 previously reported cases reflect an aggressive tumor growth with invasion, requiring partial or complete cystectomy with or without conduit diversion. We report an additional case in a 40-yr-old woman with a living related renal transplant, who experienced rapid progression of her tumor over 3 wk from initial hematuria to a pelvic mass involving the anterior bladder. Her allograft ureter and native ureters, as well as her left iliac vein, became obstructed with tumor in another 2 wk. Biopsy showed poorly differentiated, invasive transitional carcinoma. Attempted resection was abandoned because of finding tumor involvement in most of the pelvis. Chemotherapy was not attempted. She died 2 wk after her attempted resection from tumor burden. Our report presents a collective review of these previously reported 11 cases plus our case. These bladder tumors demonstrate a rapid progression of invasive disease and respond poorly to chemotherapy. There is a possible association of bladder tumors with cyclophosphamide immunosuppression. An aggressive surgical approach should be followed, especially since these tumors present in a younger age group.
Gifford
R R
RR
Department of Surgery, University of South Carolina School of Medicine, and Richland Memorial Hospital, Columbia, USA.
Wofford
J E
JE
Edwards
W G
WG
D000328:Adult; D002295:Carcinoma, Transitional Cell / Q000209:etiology* / Q000473:pathology; D003520:Cyclophosphamide / Q000009:adverse effects; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation / Q000276:immunology; D011183:Postoperative Complications; D001749:Urinary Bladder Neoplasms / Q000209:etiology* / Q000473:pathology
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide